Drug intelligence / Profile preview

Regeneris Celutone

Development stage: Unknown
Lead developer: Regeneris Medical
Modality: Cell Therapies
Administration: Subcutaneous, Topical

Overview

Regeneris Celutone is an aesthetic regenerative procedure developed by Regeneris Medical for the treatment of cellulite. The treatment is a multi-modal, 30-minute in-office procedure that combines three distinct components: a biologic treatment utilizing autologous adipose-derived regenerative cells and platelet-rich plasma (PRP) to enhance skin texture and promote dermal healing; a mechanical component using the Avéli device to release the fibrous septa bands that cause cellulite dimples; and a proprietary topical skin toning cream for maintenance. This combination approach targets both the structural causes of cellulite and the overall quality and tone of the overlying skin.

Brand names: Regeneris Celutone
Other names: Celutone

Beyond the preview

Go deeper on Regeneris Celutone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regeneris Celutone.

Explore the full profile